neuropsychiatric

Digital therapeutics pioneer Akili Interactive Labs goes public, raising $150M+; trades down 49% first day

by

Akili Inter­ac­tive is the lat­est com­pa­ny to go pub­lic via SPAC deal (Boston Busi­ness Journal):

Boston’s Akili Inter­ac­tive Labs Inc. is the lat­est Mass­a­chu­setts-based com­pa­ny to go pub­lic after com­plet­ing a reverse merg­er — in a year of mar­ket tur­moil that saw few local firms pass­ing the thresh­old between pri­vate and pub­lic status.

Shares of Akili start­ed trad­ing on Mon­day on the Nas­daq Cap­i­tal Mar­ket under the new tick­er sym­bol “AKLI” after the com­pa­ny com­plet­ed its pre­vi­ous­ly announced reverse merg­er with Social Cap­i­tal Suvret­ta Hold­ings Corp. I (Nas­daq: DNAA), a spe­cial pur­pose acqui­si­tion com­pa­ny, or SPAC. [Read more…] about Dig­i­tal ther­a­peu­tics pio­neer Akili Inter­ac­tive Labs goes pub­lic, rais­ing $150M+; trades down 49% first day

Digital therapeutics pioneer Akili Interactive plans to go public in mid-2022 at a $1B valuation

by

Pal­i­hapi­tiya-Led SPAC to Merge With Akili in $1 Bil­lion Deal (Bloomberg):

Akili Inter­ac­tive, a start­up that has devel­oped a video game to help treat atten­tion-deficit dis­or­ders in kids, has agreed to go pub­lic through a merg­er with one of Chamath Palihapitiya’s blank-check companies.

The deal, which con­firms a Bloomberg News report, val­ues the com­bined enti­ty at about $1 bil­lion, Akili and Social Cap­i­tal Suvret­ta Hold­ings Corp. I said in a state­ment seen by Bloomberg. It will pro­vide as much as $412 mil­lion in gross cash pro­ceeds, the com­pa­nies said. [Read more…] about Dig­i­tal ther­a­peu­tics pio­neer Akili Inter­ac­tive plans to go pub­lic in mid-2022 at a $1B valuation

Study: Personalized, closed-loop neuromodulation can (one day) become a “pacemaker for the brain”

by

Click image above to watch 2‑minute video explain­ing the study

Treat­ing Severe Depres­sion with On-Demand Brain Stim­u­la­tion (UCSF press release):

UCSF Health physi­cians have suc­cess­ful­ly treat­ed a patient with severe depres­sion by tap­ping into the spe­cif­ic brain cir­cuit involved in depres­sive brain pat­terns and reset­ting them using the equiv­a­lent of a pace­mak­er for the brain.

“This study points the way to a new par­a­digm that is des­per­ate­ly need­ed in psy­chi­a­try,” said Andrew Krys­tal, PhD, pro­fes­sor of psy­chi­a­try and mem­ber of the UCSF Weill Insti­tute for Neu­ro­sciences. “We’ve devel­oped a pre­ci­sion-med­i­cine approach that has suc­cess­ful­ly man­aged our patient’s treat­ment-resis­tant depres­sion by iden­ti­fy­ing and mod­u­lat­ing the cir­cuit in her brain that’s unique­ly asso­ci­at­ed with her symp­toms.” [Read more…] about Study: Per­son­al­ized, closed-loop neu­ro­mod­u­la­tion can (one day) become a “pace­mak­er for the brain”

Click Therapeutics and Boehringer Ingelheim partner to develop and market a digital therapeutic to treat schizophrenia

by

Boehringer Ingel­heim, Click Ther­a­peu­tics ink $500M+ dig­i­tal ther­a­peu­tics devel­op­ment, com­mer­cial­iza­tion deal (Mobi­Health­News):

Inter­na­tion­al phar­ma Boehringer Ingel­heim and pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Click Ther­a­peu­tics have inked a $500 mil­lion-plus deal to joint­ly devel­op and com­mer­cial­ize a dig­i­tal treat­ment for patients with schiz­o­phre­nia. [Read more…] about Click Ther­a­peu­tics and Boehringer Ingel­heim part­ner to devel­op and mar­ket a dig­i­tal ther­a­peu­tic to treat schizophrenia

Survey finds ischaemic stroke and altered mental status as most common neurological complications in severe COVID-19 cases

by

Brain dam­age, psy­chi­atric prob­lems report­ed in severe coro­n­avirus cas­es, study says (Mia­mi Herald):

A new study shows that severe cas­es of the coro­n­avirus can cause strokes and oth­er neu­ro­log­i­cal issues, or an “altered men­tal state” for patients.

The research, pub­lished in the British med­ical jour­nal Lancet Psy­chi­a­try, looked at a small pool of severe COVID-19 cas­es. The researchers found more than 100 patients who had either neu­ro­log­i­cal or psy­chi­atric prob­lems from the coronavirus.

[Read more…] about Sur­vey finds ischaemic stroke and altered men­tal sta­tus as most com­mon neu­ro­log­i­cal com­pli­ca­tions in severe COVID-19 cases

Epigenetics research opens potential door to prevent neurodevelopmental disorders

by

Sai Ma, for­mer Vir­ginia Tech bio­med­ical engi­neer­ing Ph.D. stu­dent, and Chang Lu, the Fred W. Bull pro­fes­sor of Chem­i­cal Engi­neer­ing at Vir­ginia Tech. Cred­it: Vir­ginia Tech

___

Epi­ge­net­ic Changes Guide Devel­op­ment of Dif­fer­ent Brain Regions (Dana Foundation):

“It’s one of the great­est stand­ing mys­ter­ies in neu­ro­science: Giv­en that each cell in the human body con­tains the same DNA, how, exact­ly, does the brain devel­op into dis­tinct func­tion­al regions, sup­port­ed by dif­fer­ent cell types? And how might that devel­op­men­tal pro­gram go awry, result­ing in neu­rode­vel­op­men­tal dis­or­ders like schiz­o­phre­nia or autism? The answers may be the epigenome [Read more…] about Epi­ge­net­ics research opens poten­tial door to pre­vent neu­rode­vel­op­men­tal disorders